<p>Russell Poulter of the University of Otago in New Zealand will use a microbial biosynthesis platform to develop cyclic analogues of the viral protein Tat, which is major regulator of HIV transcription, and test their ability to activate latent HIV. The reactivated HIV would be susceptible to retroviral therapies enabling comprehensive killing of HIV infected cells.</p>


Russell Poulter of the University of Otago in New Zealand will use a microbial biosynthesis platform to develop cyclic analogues of the viral protein Tat, which is major regulator of HIV transcription, and test their ability to activate latent HIV. The reactivated HIV would be susceptible to retroviral therapies enabling comprehensive killing of HIV infected cells.